<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933357</url>
  </required_header>
  <id_info>
    <org_study_id>RO2010-30912</org_study_id>
    <nct_id>NCT04933357</nct_id>
  </id_info>
  <brief_title>Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy ï¿¼</brief_title>
  <acronym>MART</acronym>
  <official_title>Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy Using Functional Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective trial evaluating dose escalation using an SBRT boost to poor-&#xD;
      responding tumors by interim functional imaging (PET/CT and fMRI) to improve the local&#xD;
      control of HNCSCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco-regional control of HNSCC patients.</measure>
    <time_frame>2 years loco-regional control.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute radiation toxicity</measure>
    <time_frame>During treatment and up to 6 months post treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between different parameters of PET/CT and fMRI in assessing response to treatment.</measure>
    <time_frame>2-4 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years overall survival</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dose escalation</intervention_name>
    <description>Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost</description>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard dose</intervention_name>
    <description>Standard dose to good responders to achieve dose equivalent of 70 Gy.</description>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than or equal to 18 years old. ECOG Performance Scale (0-2). Histological&#xD;
             confirmation of SCC of the oral cavity, oropharynx, nasopharynx, hypopharynx or&#xD;
             larynx.&#xD;
&#xD;
        Clinical stage II-IVB (AJCC, 8th edition). Multidisciplinary decision of radical radiation&#xD;
        or concurrent chemoradiotherapy (CCRT).&#xD;
&#xD;
        Informed consent obtained, signed and dated before specific protocol procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage I/II glottic cancer. Patients who underwent surgery for the primary tumor&#xD;
             location. Distant metastases. Inability to undergo PET-CT or MRI. Prior invasive&#xD;
             malignancy (except non-melanomatous skin cancer) unless disease- free for a minimum of&#xD;
             5 years. Prior radiotherapy to the region of the head and neck that would result in&#xD;
             overlap of radiation fields. Any psychological, familial, sociological or geographical&#xD;
             condition that hamper compliance with the study and/ or follow up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Shouman</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roa El-Tagy</last_name>
    <phone>002-01222410771</phone>
    <email>roa.eltagy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>May Ashour</last_name>
    <email>may25s@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roa El-Tagy</last_name>
      <email>roa.eltagy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Roa AbdulRahim El-Tagy</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

